Oramed Pharmaceuticals Inc (ORMP):企業の財務・戦略的SWOT分析

◆英語タイトル:Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH63306FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Oramed Pharmaceuticals Inc (ORMP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oramed Pharmaceuticals Inc (Oramed) is a pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes, and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York, the US.

Oramed Pharmaceuticals Inc Key Recent Developments

Mar 22,2021: Oramed forms joint venture to develop new oral vaccines for Covid-19
Nov 12,2020: Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be featured on biotalknology webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020
Oct 16,2020: Oramed issues shareholder update on pivotal phase 3 oral insulin studies: protocols submitted to FDA
Aug 04,2020: Oramed Pharmaceuticals: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Mar 19,2020: Oramed receives positive feedback from end-of-phase 2 oral insulin CMC meeting with FDA

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Oramed Pharmaceuticals Inc – Key Facts
Oramed Pharmaceuticals Inc – Key Employees
Oramed Pharmaceuticals Inc – Key Employee Biographies
Oramed Pharmaceuticals Inc – Major Products and Services
Oramed Pharmaceuticals Inc – History
Oramed Pharmaceuticals Inc – Company Statement
Oramed Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Oramed Pharmaceuticals Inc – Business Description
R&D Overview
Oramed Pharmaceuticals Inc – Corporate Strategy
Oramed Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Oramed Pharmaceuticals Inc – Strengths
Oramed Pharmaceuticals Inc – Weaknesses
Oramed Pharmaceuticals Inc – Opportunities
Oramed Pharmaceuticals Inc – Threats
Oramed Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 22, 2021: Oramed forms joint venture to develop new oral vaccines for Covid-19
Nov 12, 2020: Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be featured on biotalknology webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020
Oct 16, 2020: Oramed issues shareholder update on pivotal phase 3 oral insulin studies: protocols submitted to FDA
Aug 04, 2020: Oramed Pharmaceuticals: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jan 30, 2020: Oramed appoints Dr. Julio Rosenstock to its Scientific Advisory Board
Jan 28, 2020: Oramed patent in Europe to be granted for oral delivery of proteins
Jan 23, 2020: Oramed elects Dr. Alexander Fleming to Scientific Advisory Board
Jan 21, 2020: Oramed appoints Dr. Jay Skyler to Scientific Advisory Board
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Oramed Pharmaceuticals Inc, Key Facts
Oramed Pharmaceuticals Inc, Key Employees
Oramed Pharmaceuticals Inc, Key Employee Biographies
Oramed Pharmaceuticals Inc, Major Products and Services
Oramed Pharmaceuticals Inc, History
Oramed Pharmaceuticals Inc, Subsidiaries
Oramed Pharmaceuticals Inc, Joint Venture
Oramed Pharmaceuticals Inc, Key Competitors
Oramed Pharmaceuticals Inc, Ratios based on current share price
Oramed Pharmaceuticals Inc, Annual Ratios
Oramed Pharmaceuticals Inc, Annual Ratios (Cont...1)
Oramed Pharmaceuticals Inc, Interim Ratios
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Oramed Pharmaceuticals Inc (ORMP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Avon Rubber Plc (AVON):企業の財務・戦略的SWOT分析
    Avon Rubber Plc (AVON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Burgan Bank Sak:企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Formosa Chemicals & Fibre Corp (1326):企業の財務・戦略的SWOT分析
    Formosa Chemicals & Fibre Corp (1326) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Close Brothers Asset Management:企業の戦略・SWOT・財務情報
    Close Brothers Asset Management - Strategy, SWOT and Corporate Finance Report Summary Close Brothers Asset Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PUMA SE:企業の戦略・SWOT・財務情報
    PUMA SE - Strategy, SWOT and Corporate Finance Report Summary PUMA SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Bioanalytical Systems Inc (BASI):企業の財務・戦略的SWOT分析
    Summary Bioanalytical Systems Inc (Bioanalytical Systems) is a contract research organization that provides drug discovery and development services, and analytical instruments. The company’s contract research services include screening and pharmacological testing, formulation development, preclinica …
  • Ormat Technologies Inc (ORA):企業の財務・戦略的SWOT分析
    Ormat Technologies Inc (ORA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Segafredo Zanetti S.p.A.:企業の戦略・SWOT・財務情報
    Segafredo Zanetti S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Segafredo Zanetti S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • TechnipFMC Plc (FTI):企業の財務・戦略的SWOT分析
    TechnipFMC Plc (FTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Nikon Corporation:企業の戦略・SWOT・財務情報
    Nikon Corporation - Strategy, SWOT and Corporate Finance Report Summary Nikon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • P. H. Glatfelter Company (GLT):企業の財務・戦略的SWOT分析
    P. H. Glatfelter Company (GLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • James Cropper PLC (CRPR):企業の財務・戦略的SWOT分析
    James Cropper PLC (CRPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Helomics Corp-製薬・医療分野:企業M&A・提携分析
    Summary Helomics Corp(Helomics) is a life science company that develops and offers precision medicine support tools and services for cancer treatment. The company’s products include chemofx, biospecifx, genefx colon and genefx lung. Its chemofx is a drug response marker, which is used to test tumor …
  • Synthomer plc (SYNT):企業の財務・戦略的SWOT分析
    Synthomer plc (SYNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • CH2M HILL Companies, Ltd.:戦略・SWOT・企業財務分析
    CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report Summary CH2M HILL Companies, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • FHI 360:企業の戦略的SWOT分析
    FHI 360 - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Peters Surgical:医療機器:M&Aディール及び事業提携情報
    Summary Peters Surgical (Peters), a subsidiary of Eurazeo SA, is a medical device company that designs, manufactures and distributes surgical products. The company offers products such as catheters, sutures, surgical glue, cardiac ring, single use instrument and accessories for surgical procedures. …
  • Enterome Bioscience SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Enterome Bioscience SA (Enterome) is a drug development company which develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome …
  • Vaccitech Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Vaccitech Ltd (Vaccitech) is a clinical stage company that focuses on the development of universal flu vaccines. The company is developing clinical programs for the treatment of influenza, prostate cancer, HBV, Middle East respiratory syndrome (MERS), shingles, human papillomavirus (HPV), an …
  • Wynn Macau Ltd:戦略・SWOT・企業財務分析
    Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report Summary Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆